Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2NET 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 9Carcinoma, Neuroendocrine 2Carcinoid Tumor 2Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Non functioning pancreatic endocrine tumor 1Metastatic Digestive System Neuroendocrine Tumor G1 1Gastro-enteropancreatic neuroendocrine tumor 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

Everolimus 6Sunitinib 3Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Injections 2recombinant interferon alpha 2b-like protein 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1fludarabine phosphate 1cabozantinib 1batifiban 1abemaciclib 1X-Rays 1Sorafenib 1Phantoms, Imaging 1PM 01183 1Oxaliplatin 1Leucovorin 1Interleukin-13 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cryotherapy 1Biopsy 1Bevacizumab 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × cabozantinib × NET × Clear all
NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡